Pfizer partners with Sciwind Biosciences to market diabetes treatment in China
Pfizer has secured rights to market Sciwind's diabetes drug ecnoglutide in China. The deal includes potential milestone payments totaling 495 million dollars.
Insights:
Pfizer Inc. announced on February 24, 2026, that it has entered into a licensing agreement with Sciwind Biosciences to commercialize ecnoglutide, a type 2 diabetes treatment, in mainland China 
CN. Under the terms of the agreement, Pfizer will manage the commercialization of the drug in the region, with Sciwind Biosciences eligible to receive potential milestone payments of up to $495 million if specific targets are met.
CN. Under the terms of the agreement, Pfizer will manage the commercialization of the drug in the region, with Sciwind Biosciences eligible to receive potential milestone payments of up to $495 million if specific targets are met.Ecnoglutide is a GLP-1 receptor agonist that was recently approved for use in China in January. The deal is described as a material advancement of Pfizer's metabolic strategy in the country, securing the rights to a newly authorized therapy in a rapidly expanding therapeutic class. The agreement specifically governs the commercialization terms for the mainland market following the drug's regulatory clearance.
